The Amendment Group was founded by Chairman Xiu Laigui in May 1995. It is a large-scale modern private pharmaceutical enterprise integrating the scientific research, production and marketing of Chinese patent medicines, chemical pharmaceuticals, and biopharmaceuticals, drug chain operations, and standard cultivation of Chinese medicinal materials.
The revision group has 127 subsidiaries with more than 170,000 employees. It has 24 dosage forms, more than 2000 varieties of medicine and health products. The revision group has been booming for many years and its scale has been expanding. Its revenue will 60 billion in 2018, 70 billion in 2019 and 100 billion in 2020.